Bluebomber6 wrote: Well, boys and girls, there you have it, infuriated by Bunge's posts, Bencro could no longer stay quiet, pretend that he was rational any longer, like a coming, Bencro exploded onto our screens!! Letting all you guys know, forget about one pp, screw that, you suckers are getting two of them and you will love all the things they will do to you!!
Thank you, Bencro for being honest with us. How do you know this? Where did you get this info?
Sure fits with everything RW was orchestrating for his last 10 months, minimizing for a few more pps, taking more value away from loyal shareholders with each pp, while the moneylenders take our company away from us
. Interesting that a jv is in the cards, but not just yet, after the two pps, after shareholders have been fleeced? Then we go for the jv, huh.
Why would anyone now buy after first pp, when another coming, very revealing of you, Bencro.
You just cant hide who you really are working for, can you??
bencro wrote: "Magical thinking" Bunge ... I know you like to sound "sexy" with your WannaBeCEO high expectations regarding a new external CEO, but a new external CEO won't change much. For many reasons:
- TLT is not a multinational where you have lots of meat to cut in. It's not GE for example
- kitty running low, at least one pp will already be a reality before a new external CEO arrives.
- 2nd pp (if they decide for the short term to go with one small one that brings us up to the Ph. 1b data (e.g. Sept.)) will be based mostly on the quality of the 6-month efficacy data observed in the Ph. 1b. So nothing to do with the arrival of a new external CEO. If data is excellent, even Bunge could negociate one and look like a genius.
- they already re-confirmed the orientation regarding the NMIBC Ph. 2b direction (it will be a pp, not a jv). JV will be once they have Ph. 2b data, as Echelon Partners was talking about possible 35% royalties (found this a bit high though).
- they already comitted to TLC-2000 re-design. Dropping this would mean laying off staff that also build and design laser related technologies (TLC-3200, DOFC (TLC-3400), TLC-2000, TLC-900, TLC-1000, future CLT, future optical-related technologies for cervical cancer, lung cancer, brain cancer, etc ...). Profit margins (as per Echelon and financials) are 68%-70%. Hard to say no to such margins.
- TLT had already hinted us that for the brain clinical trial, they were looking for a jv, because of high costs. So a new external CEO won't do any magic on this.
- NSCLC indication is a major one but still in pre-clinical stages. But for the moment, this seems to have been postponed, until otherwise stated.
- CLT was planned to be linked (and will still be) with a distribution deal with a big pharma that already had an established distribution network across oncologists, as TLT has no time, nor the money to develop such network. So nothing to do with the arrival of a new external CEO, as this one was a no brainer given the major revenues that it could bring in the kitty. But for the moment, this seems to have been postponed, until otherwise stated.
- etc ...